Recent Publications

Reshetnyak AV, Murray PB, Shi X, Mo ES, Mohanty J, Tome F, Bai H, Gunel M, Lax I, Schlessinger J.
Proc Natl Acad Sci U S A. 2015 Nov 16. 

Haskins JW, Zhang S, Means RE, Kelleher JK, Cline GW, Canfrán-Duque A, Suárez Y, Stern DF.
Sci Signal. 2015 Nov 3;8(401):ra111. 

Langdon CG, Wiedemann N, Held MA, Mamillapalli R, Iyidogan P, Theodosakis N, Platt JT, Levy F, Vuagniaux G, Wang S, Bosenberg MW, Stern DF.
Oncotarget. 2015 Oct 16. 

Sonpavde G, Pond GR, Templeton AJ, Fandi A, Tombal B, Rosenthal M, Armstrong AJ, Petrylak DP.
Eur Urol. 2015 Oct 20. 

Pirazzoli V, Ayeni D, Meador CB, Sanganahalli B, Hyder F, de Stanchina E, Goldberg SB, Pao W, Politi K.
Clin Cancer Res. 2015 Sep 4.

Wilson MA, Zhao F, Khare S, D'Andrea K, Wubbenhorst B, Roszik J, Woodman SE, Rimm DL, Kirkwood JM, Kluger HM, Schuchter LM, Lee SJ, Flaherty KT, Nathanson KL.
Copy number changes are associated with response to treatment with carboplatin, paclitaxel, and sorafenib in melanoma.
Clin Cancer Res. 2015 Aug 25.

Li Q, Tsuneki M, Krauthammer M, Couture R, Schwartz M, Madri JA.
Am J Pathol. 2015 Jul 22.

Krauthammer M, Kong Y, Bacchiocchi A, Evans P, Pornputtapong N, Wu C, McCusker JP, Ma S, Cheng E, Straub R, Serin M, Bosenberg M, Ariyan S, Narayan D, Sznol M, Kluger HM, Mane S, Schlessinger J, Lifton RP, Halaban R.
Nat Genet. 2015 Jul 27.  

Hurwitz M.
Curr Oncol Rep. 2015 Oct;17(10):468. 

Myung P, Greco V.
Cell. 2015 Jul 30;162(3):476-7. 

Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, Carlson K, Overton JD, Liu KJ, Lewis JM, Devine L, Barbarotta L, Foss FM, Subtil A, Vonderheid EC, Edelson RL, Schatz DG, Boggon TJ, Girardi M, Lifton RP. 
Nat Genet. 2015 Jul 20.

Chakraborty AK, Zerillo C, DiGiovanna MP. 

Breast Cancer Res Treat. 2015 Jul 21.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.
J Urol. 2015 Jul 18.

Ayeni D, Politi K, Goldberg SB.
Clin Cancer Res. 2015 Jul 13.

Pineda CM, Park S, Mesa KR, Wolfel M, Gonzalez DG, Haberman AM, Rompolas P, Greco V.
Nat Protoc. 2015 Jul;10(7):1116-30.

Ji W, Li Y, He Y, Yin M, Zhou HJ, Boggon TJ, Zhang H, Min W.
Cancer Res. 2015 Jul 2.

Theodosakis N 2nd, Held MA, Marzuka-Alcalá A, Meeth K, Micevic G, Long GV, Scolyer RA, Stern DF, Bosenberg MW.

Mol Cancer Ther. 2015 May 6.

Mesa KR, Rompolas P, Zito G, Myung P, Sun TY, Brown S, Gonzalez DG, Blagoev KB, Haberman AM, Greco V.
Nature. 2015 Apr 6. doi: 10.1038/nature14306.

Simpson MA, Bradley WD, Harburger D, Parsons M, Calderwood DA, Koleske AJ.
J Biol Chem. 2015 Feb 18.

Daniel Morgensztern, MD1; Katerina Politi, PhD; Roy S. Herbst, MD, PhD
JAMA Oncol. Published online February 26, 2015.

Petrylak DP, Gandhi JG, Clark WR, Heath E, Lin J, Oh WK, Agus DB, Carthon B, Moran S, Kong N, Suri A, Bargfrede M, Liu G.
Invest New Drugs. 2015 Jan 4.


Hafez N, Petrylak DP.



emptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyCould PD-L1 prove to be an effective therapeutic target for bladder cancer?


Immunotherapy. 2015;7(1):1-2. 


Arnal-Estapé A, Nguyen DX.
Cancer Discov. 2015 Feb;5(2):109-11.

Jin L, Li D, Alesi GN, Fan J, Kang HB, Lu Z, Boggon TJ, Jin P, Yi H, Wright ER, Duong D, Seyfried NT, Egnatchik R, DeBerardinis RJ, Magliocca KR, He C, Arellano ML, Khoury HJ, Shin DM, Khuri FR, Kang S.
Cancer Cell. 2015 Feb 9;27(2):257-70. 

Acevedo-Gadea C, Hatzis C, Chung G, Fishbach N, Lezon-Geyda K, Zelterman D, DiGiovanna MP, Harris L, Abu-Khalaf MM.
Breast Cancer Res Treat. 2015 Feb 17.

Lu Y, Xue Q, Eisele MR, Sulistijo ES, Brower K, Han L, Amir EA, Pe'er D, Miller-Jensen K, Fan R.
Proc Natl Acad Sci U S A. 2015 Feb 2.

Rothlin CV, Carrera-Silva EA, Bosurgi L, Ghosh S.
Annu Rev Immunol. 2015 Jan 14.

Song X, Fan PD, Bantikassegn A, Guha U, Threadgill DW, Varmus H, Politi K.
Cancer Res. 2015 Jan 16.

Murray PB, Lax I, Reshetnyak A, Ligon GF, Lillquist JS, Natoli EJ Jr, Shi X, Folta-Stogniew E, Gunel M, Alvarado D, Schlessinger J.
Sci Signal. 2015 Jan 20;8(360):ra6.

Song X, Fan PD, Bantikassegn A, Guha U, Threadgill DW, Varmus H, Politi K.
Cancer Res. 2015 Jan 16.
Abu-Khalaf MM, Baumgart MA, Gettinger SN, Doddamane I, Tuck DP, Hou S, Chen N, Sullivan C, Lezon-Geyda K, Zelterman D, Hatzis C, Deshpande H, Digiovanna MP, Azodi M, Schwartz PE, Harris LN.
Cancer. 2015 Feb 3.

Wimberly H, Brown JR, Schalper KA, Haack H, Silver MR, Nixon C, Bossuyt V, Pusztai L, Lannin DR, Rimm DL.
Cancer Immunol Res. 2014 Dec 19. 

Reshetnyak AV, Opatowsky Y, Boggon TJ, Folta-Stogniew E, Tome F, Lax I, Schlessinger J.
Mol Cell. 2014 Dec 23.

Petrylak DP, Gandhi JG, Clark WR, Heath E, Lin J, Oh WK, Agus DB, Carthon B, Moran S, Kong N, Suri A, Bargfrede M, Liu G.
Invest New Drugs. 2015 Jan 4.

Bhatnagar S, Gazin C, Chamberlain L, Ou J, Zhu X, Tushir JS, Virbasius CM, Lin L, Zhu LJ, Wajapeyee N, Green MR. 
Nature. 2014 Dec 4;516(7529):116-20.

Agarwal S, Hanna J, Sherman ME, Figueroa J, Rimm DL. 
Br J Cancer. 2014 Dec 4.

Meador CB, Jin H, de Stanchina E, Nebhan CA, Pirazzoli V, Wang L, Lu P, Vuong H, Hutchinson KE, Jia P, Chen X, Eisenberg R, Ladanyi M, Politi K, Zhao Z, Lovly CM, Cross DA, Pao W. 
Mol Cancer Ther. 2014 Dec 4.

Brown S, Greco V. 
Cell Stem Cell. 2014 Dec 4;15(6):683-6.

Golden D, Cantley LG. 
Oncogene. 2014 Dec 8.

Gupta R, Liu AY, Glazer PM, Wajapeyee N. 
Nucleic Acids Res. 2014 Dec 8.

Haskins JW, Nguyen DX, Stern DF. 
Sci Signal. 2014 Dec 9;7(355):ra116. 

Bantikassegn A, Song X, Politi K.

Isolation of Epithelial, Endothelial, and Immune Cells From Lungs of Transgenic Mice with Oncogene-Induced Lung Adenocarcinomas.

Am J Respir Cell Mol Biol. 2014 Oct 27


Bantikassegn A, Song X, Politi K.



emptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyIsolation of Epithelial, Endothelial, and Immune Cells From Lungs of Transgenic Mice with Oncogene-Induced Lung Adenocarcinomas.


Am J Respir Cell Mol Biol. 2014 Oct 27.

Jilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, Rimm DL, Bosenberg MW, Halaban R, Kluger Y, Kluger HM.
PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.
Clin Cancer Res. 2014 Oct 14.

Ma C, Fan R.
Cancer immunotherapy and next-generation clinical immune assessment.
Front Oncol. 2014 Sep 24;4:265.

Jilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, Rimm DL, Bosenberg MW, Halaban R, Kluger Y, Kluger HM.
PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.
Clin Cancer Res. 2014 Oct 14.

Simpson CA, Cusano AM, Bihuniak J, Walker J, Insogna KL.
Effect of 25(OH) vitamin D reference method procedure (RMP) alignment on clinical measurements obtained with the IDS-iSYS chemiluminescent-based automated analyzer.
J Steroid Biochem Mol Biol. 2014 Sep 18

Wang EH, Yu JB, Gross CP, Smaldone MC, Shah ND, Trinh QD, Nguyen PL, Sun M, Han LC, Kim SP.
Variation in Pelvic Lymph Node Dissection Among Patients Undergoing Radical Prostatectomy by Hospital Characteristics and Surgical Approach: Results from the National Cancer Database.
J Urol. 2014 Sep 18.

Brown J, Wimberly H, Lannin DR, Nixon C, Rimm DL, Bossuyt V.
Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer.
Clin Cancer Res. 2014 Sep 25.

Han L, Zi X, Garmire LX, Wu Y, Weissman SM, Pan X, Fan R.
Co-detection and sequencing of genes and transcripts from the same single cells facilitated by a microfluidics platform.
Sci Rep. 2014 Sep 26;4:6485.

Tsuneki M, Madri JA.
Adhesion Molecule-Mediated Hippo Pathway Modulates Hemangioendothelioma Cell Behavior.
Mol Cell Biol. 2014 Sep 29.

Politi K, Gettinger S.
Perfect ALKemy: Optimizing the Use of ALK-Directed Therapies in Lung Cancer.
Clin Cancer Res. 2014 Sep 16.

Shipitsin M, Small C, Giladi E, Siddiqui S, Choudhury S, Hussain S, Huang YE, Chang H, Rimm DL, Berman DM, Nifong TP, Blume-Jensen P.
Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality.
Proteome Sci. 2014 Jul 12;12:40.

Nagarajan A, Roden C, Wajapeyee N.
Reduced representation bisulfite sequencing to identify global alteration of DNA methylation.
Methods Mol Biol. 2014;1176:23-31.

Hurwitz ME.
Clonal Screens to Find Modifiers of Partially Penetrant Phenotypes in C. elegans.
Methods Mol Biol. 2014;1176:157-67.

Evans P, Kong Y, Krauthammer M.
Computational analysis in cancer exome sequencing.
Methods Mol Biol. 2014;1176:219-27.

Lu Y, Wajapeyee N, Turker MS, Glazer PM.
Silencing of the DNA Mismatch Repair Gene MLH1 Induced by Hypoxic Stress in a Pathway Dependent on the Histone Demethylase LSD1.
Cell Rep. 2014 Jul 15.

Bonasio R, Lecona E, Narendra V, Voigt P, Parisi F, Kluger Y, Reinberg D.
Interactions with RNA direct the Polycomb group protein SCML2 to chromatin where it represses target genes.
Elife. 2014 Jul 1;3:e02637.

Cheng H, Bai Y, Sikov W, Sinclair N, Bossuyt V, Abu-Khalaf MM, Harris LN, Rimm DL.
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab.
BMC Cancer. 2014 May 8;14(1):326.

Petrylak DP.
Practical guide to the use of chemotherapy in castration resistant prostate cancer.
Can J Urol. 2014 Apr;21(2 Supp 1):77-83.

Valentina Pirazzoli, Caroline Nebhan, Xiaoling Song, Anna Wurtz, Zenta Walther, Guoping Cai, Zhongming Zhao, Peilin Jia, Elisa de Stanchina, Erik M. Shapiro, Molly Gale, Ruonan Yin, Leora Horn, David Carbone, Philip J Stephens, Vincent Miller, Scott Gettinger, William Pao and Katerina Politi
Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1

Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, Miller V, Gettinger S, Pao W, Politi K.
Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1.
Cell Rep. 2014 May 7.

Wali VB, Haskins JW, Gilmore-Hebert M, Platt JT, Liu Z, Stern DF
Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells.
Mol Cancer Res. 2014 May 14.

Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL.
In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas.
Clin Cancer Res. 2014 May 15;20(10):2773-82.

Nagarajan A, Dogra SK, Liu AY, Green MR, Wajapeyee N.
PEA15 regulates the DNA damage induced cell cycle checkpoint and oncogene-directed transformation.
Mol Cell Biol. 2014 Apr 7.

Cao J, Liu Z, Cheung WK, Zhao M, Chen SY, Chan SW, Booth CJ, Nguyen DX, Yan Q.
Histone Demethylase RBP2 Is Critical for Breast Cancer Progression and Metastasis.
Cell Rep. 2014 Feb 25.

de Bono JS, Piulats JM, Pandha HS, Petrylak DP, Saad F, Antón-Aparicio LM, Sandhu SK, Fong P, Gillessen S, Hudes GR, Wang T, Scranton J, Pollak MN.
Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res. 2014 Feb 17.

Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL.
In situ Tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.
Clin Cancer Res. 2014 Mar 19. 

Deschene ER, Myung P, Rompolas P, Zito G, Sun TY, Taketo MM, Saotome I, Greco V.
β-Catenin activation regulates tissue growth non-cell autonomously in the hair stem cell niche.
Science. 2014 Mar 21;343(6177):1353-6.

Zito G, Saotome I, Liu Z, Ferro EG, Sun TY, Nguyen DX, Bilguvar K, Ko CJ, Greco V.
Spontaneous tumour regression in keratoacanthomas is driven by Wnt/retinoic acid signalling cross-talk.
Nat Commun. 2014 Mar 26;5:3543.

Neumeister VM, Parisi F, England AM, Siddiqui S, Anagnostou V, Zarrella E, Vassilakopolou M, Bai Y, Saylor S, Sapino A, Kluger Y, Hicks DG, Bussolati G, Kwei S, Rimm DL.
A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue.
Lab Invest. 2014 Feb 17.

de Bruin EC, Cowell CF, Warne PH, Jiang M, Saunders RE, Melnick MA, Gettinger SN, Walther Z, Wurtz A, Heynen GJ, Heideman DA, Gomez-Roman JJ, García-Castaño A, Gong Y, Ladanyi M, Varmus H, Bernards R, Smit EF, Politi K, Downward J.
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.
Cancer Discov. 2014 Feb 17.

Guo S, Zi X, Schulz VP, Cheng J, Zhong M, Koochaki SH, Megyola CM, Pan X, Heydari K, Weissman SM, Gallagher PG, Krause DS, Fan R, Lu J.
Nonstochastic Reprogramming from a Privileged Somatic Cell State.
Cell. 2014 Jan 28. pii: S0092-8674(14)00072-5.

Pirazzoli V, Politi K.
Generation of drug-resistant tumors using intermittent dosing of tyrosine kinase inhibitors in mouse.
Cold Spring Harb Protoc. 2014 Feb 1;2014(2).

Petrylak DP.
Challenges in treating advanced disease.
Am J Manag Care. 2013 Dec;19(18 Suppl):s366-75.

Opatowsky Y, Lax I, Tomé F, Bleichert F, Unger VM, Schlessinger J.
Structure, domain organization, and different conformational states of stem cell factor-induced intact KIT dimers.
Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1772-7.

William Lockwood and Katerina Politi
MYCxing It Up with FGFR1 in Squamous Cell Lung Cancer
Cancer Discovery February 2014 4:152-154; doi:10.1158/2159-8290.

How J, Brown JR, Saylor S, Rimm DL.
Macrophage expression of tartrate-resistant acid phosphatase as a prognostic indicator in coloncancer.
Histochem Cell Biol. 2014 Jan 16.

Opatowsky Y, Lax I, Tomé F, Bleichert F, Unger VM, Schlessinger J.
Structure, domain organization, and different conformational states of stem cell factor-induced intact KIT dimers.
Proc Natl Acad Sci U S A. 2014 Jan 21.

Rompolas P, Greco V.
Stem cell dynamics in the hair follicle niche.
Semin Cell Dev Biol. 2013 Dec 17.

Malkhasyan K, Deshpande HA, Adeniran AJ, Colberg JW, Petrylak DP.
The use of serum hCG as a marker of tumor progression and of the response of metastatic urothelial cancer to systemic chemotherapy.
Oncology (Williston Park). 2013 Oct;27(10):1028, 1030.

Chen C, Ha BH, Thévenin AF, Lou HJ, Zhang R, Yip KY, Peterson JR, Gerstein M, Kim PM, Filippakopoulos P, Knapp S, Boggon TJ, Turk BE.
Identification of a Major Determinant for Serine-Threonine Kinase Phosphoacceptor Specificity.
Mol Cell. 2013 Dec 24. pii: S1097-2765(13)00863-0. 

Viray H, Li K, Long TA, Vasalos P, Bridge JA, Jennings LJ, Halling KC, Hameed M, Rimm DL.
A prospective, multi-institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells.
Arch Pathol Lab Med. 2013 Nov;137(11):1545-9.

Brown JR, Digiovanna MP, Killelea B, Lannin DR, Rimm DL.
Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer.
Lab Invest. 2013 Nov 4.

Rompolas P, Mesa KR, Greco V.
Spatial organization within a niche as a determinant of stem-cell fate.
Nature. 2013 Oct 6.

Dong Y, Richards JA, Gupta R, Aung PP, Emley A, Kluger Y, Dogra SK, Mahalingam M, Wajapeyee N.
PTEN functions as a melanoma tumor suppressor by promoting host immune response.
Oncogene. 2013 Oct 21.

Reshetnyak AV, Nelson B, Shi X, Boggon TJ, Pavlenco A, Mandel-Bausch EM, Tome F, Suzuki Y, Sidhu SS, Lax I, Schlessinger J.
Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region.
Proc Natl Acad Sci U S A. 2013 Oct 14.

Gupta R, Wajapeyee N.
Induction of Cellular Senescence by Oncogenic RAS.
Methods Mol Biol. 2013;1048:127-33.

Wilken JA, Perez-Torres M, Nieves-Alicea R, Cora EM, Christensen TA, Baron AT, Maihle NJ.
Shedding of Soluble Epidermal Growth Factor Receptor (sEGFR) Is Mediated by a Metalloprotease / Fibronectin / Integrin Axis and Inhibited by Cetuximab.
Biochemistry. 2013 Jul 2;52(26):4531-40.

Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Godwin AK, Schilder RJ, Singh M, Maihle NJ.
A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.
Gynecol Oncol. 2013 Jun;129(3):486-94.

Vanhouten JN, Wysolmerski JJ.
The calcium-sensing receptor in the breast.
Best Pract Res Clin Endocrinol Metab. 2013 Jun;27(3):403-14.

Lloyd S, Chang BW.
A comparison of three treatment strategies for locally advanced and borderline resectable pancreatic cancer.
J Gastrointest Oncol. 2013 Jun;4(2):123-30.

Cheung WK, Zhao M, Liu Z, Stevens LE, Cao PD, Fang JE, Westbrook TF, Nguyen DX.
Control of Alveolar Differentiation by the Lineage Transcription Factors GATA6 and HOPX Inhibits Lung Adenocarcinoma Metastasis.
Cancer Cell. 2013 May 21.

Velcheti V, Schalper K, Yao X, Cheng H, Kocoglu M, Dhodapkar K, Deng Y, Gettinger S, Rimm DL.
High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas.
PLoS One. 2013 Apr 19;8(4):e61427.

Kwak M, Mu L, Lu Y, Chen JJ, Brower K, Fan R.
Single-cell protein secretomic signatures as potential correlates to tumor cell lineage evolution and cell-cell interaction.
Front Oncol. 2013;3:10.

Kwak M, Mu L, Lu Y, Chen JJ, Brower K, Fan R.
Single-cell protein secretomic signatures as potential correlates to tumor cell lineage evolution and cell-cell interaction.
Front Oncol. 2013;3:10.

Abby L. Cosentino-Boehm, Jacqueline M. Lafky, Tammy M. Greenwood, Kimberly D. Kimbler, Marites C. Buenafe, Yuxia Wang, Adam J. Branscum, Ping Yang, Nita J. Maihle and Andre T. Baron.
Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma

Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD.
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.
Proc Natl Acad Sci U S A. 2013 Jan 28.

Anderson C, Zhou S, Sawin E, Horvitz HR, Hurwitz ME.
SLI-1 Cbl Inhibits the Engulfment of Apoptotic Cells in C. elegans through a Ligase-Independent Function.
PLoS Genet. 2012 Dec;8(12):e1003115.

Davis MJ, Ha BH, Holman EC, Halaban R, Schlessinger J, Boggon TJ.
RAC1P29S is a spontaneously activating cancer-associated GTPase.
Proc Natl Acad Sci U S A. 2013 Jan 2.

Goldberg SB, Schlessinger J, Boyer JL, Herbst RS.
A step towards treating KRAS-mutant NSCLC.
Lancet Oncol. 2012 Nov 27.

Wu Y, Garmire LX, Fan R.
Inter-cellular signaling network reveals a mechanistic transition in tumor microenvironment.
Integr Biol (Camb). 2012 Oct 19.

Neumeister VM, Anagnostou V, Siddiqui S, England AM, Zarrella ER, Vassilakopoulou M, Parisi F, Kluger Y, Hicks DG, Rimm DL.
Quantitative Assessment of Effect of Preanalytic Cold Ischemic Time on Protein Expression in BreastCancer Tissues.
J Natl Cancer Inst. 2012 Oct 22.

Ha BH, Davis MJ, Chen C, Lou HJ, Gao J, Zhang R, Krauthammer M, Halaban R, Schlessinger J, Turk BE, Boggon TJ.
Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate.
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16107-12.

Dimou A, Neumeister V, Agarwal S, Anagnostou V, Syrigos K, Rimm DL.
Measurement of Aldehyde Dehydrogenase 1 Expression Defines a Group with Better Prognosis in Patients with Non-Small Cell Lung Cancer.
Am J Pathol. 2012 Aug 6.

Hanna JA, Hahn L, Agarwal S, Rimm DL.
In situ measurement of miR-205 in malignant melanoma tissue supports its role as a tumor suppressor microRNA.
Lab Invest. 2012 Aug 13.

Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, Riely GJ, Kris MG, Miller VA, Ladanyi M, Politi K, Pao W.
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR mutant lung cancers that lack the second-site EGFR T790M mutation.
Cancer Discov. 2012 Sep 5.

Hahn LD, Hoyt C, Rimm DL, Theoharis C.
Spatial spectral imaging as an adjunct to the Bethesda classification of thyroid fine-needle aspiration specimens.
Cancer Cytopathol. 2012 Jul 25. 

Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, Capatana A, Holman EC, Bosenberg M, Sznol M, Kluger HM, Brash DE, Stern DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP, Schlessinger J, Boggon TJ, Halaban R.
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Nat Genet. 2012 Jul 29.

Gil-Henn H, Patsialou A, Wang Y, Warren MS, Condeelis JS, Koleske AJ.
Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo.
Oncogene. 2012 Jul 9.

Wysolmerski JJ.
Parathyroid Hormone-Related Protein: An Update.
J Clin Endocrinol Metab. 2012 Jun 28.

Feng C, Neumeister V, Ma W, Xu J, Lu L, Bordeaux J, Maihle NJ, Rimm DL, Huang Y.
Lin28 regulates HER2 and promotes malignancy through multiple mechanisms.
Cell Cycle. 2012 Jul 1;11(13).

Boras-Granic K, Wysolmerski JJ.
PTHrP and breast cancer: more than hypercalcemia and bone metastases.
Breast Cancer Res. 2012 Apr 25;14(2):307.

Macgrath SM, Koleske AJ.
Cortactin in cell migration and cancer at a glance.
J Cell Sci. 2012 Apr 1;125(Pt 7):1621-6.

Hanna JA, Wimberly H, Kumar S, Slack F, Agarwal S, Rimm DL.
Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization.
Biotechniques. 2012 Apr;52(4):235-45.

Wilken JA, Badri T, Cross S, Raji R, Santin AD, Schwartz P, Branscum AJ, Baron AT, Sakhitab AI, Maihle NJ.
EGFR/HER-targeted therapeutics in ovarian cancer.
Future Med Chem. 2012 Mar;4(4):447-69.

Baquero MT, Hanna JA, Neumeister V, Cheng H, Molinaro AM, Harris LN, Rimm DL.
Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer.
Cancer. 2012 Feb 22.

Politi K, Lynch TJ.
Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer.
Clin Cancer Res. 2012 Feb 8.

Anagnostou VK, Dimou AT, Botsis T, Killiam EJ, Gustavson MD, Homer RJ, Boffa D, Zolota V, Dougenis D, Tanoue L, Gettinger SN, Detterbeck FC, Syrigos KN, Bepler G, Rimm DL.
Molecular classification of nonsmall-cell lung cancer using a 4-protein quantitative assay.
Cancer. 2011 Aug 25. doi: 10.1002/cncr.26450

Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faça VM, Kelly-Spratt K, Wong CH, Zhang Q, Chin A, Park KS, Goodman G, Gazdar AF, Sage J, Dinulescu DM, Kucherlapati R, Depinho RA, Kemp CJ, Varmus HE, Hanash SM.
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.
Cancer Cell. 2011 Sep 13;20(3):289-99.


emptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyemptyChung, C., Mader, C.C., Schmitz, J.C., Atladottir, J., Fitchev, P., Cornwell, M.L., Koleske, A.J., Crawford, S.E., Gorelick, F.
The vacuolar-ATPase modulates matrix metalloproteinase isoforms in human pancreatic cancer
(2011) Laboratory Investigation, 91 (5), pp. 732-743.

Pectasides, E., Rampias, T., Kountourakis, P., Sasaki, C., Kowalski, D., Fountzilas, G., Zaramboukas, T., Rimm, D., Burtness, B., Psyrri, A.
Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma
(2011) Clinical Cancer Research, 17 (9), pp. 2947-2954.

Sun, T., Aceto, N., Meerbrey, K.L., Kessler, J.D., Zhou, C., Migliaccio, I., Nguyen, D.X., Pavlova, N.N., Botero, M., Huang, J., Bernardi, R.J., Schmitt, E., Hu, G., Li, M.Z., Dephoure, N., Gygi, S.P., Rao, M., Creighton, C.J., Hilsenbeck, S.G., Shaw, C.A., Muzny, D., Gibbs, R.A., Wheeler, D.A., Osborne, C.K., Schiff, R., Bentires-Alj, M., Elledge, S.J., Westbrook, T.F.
Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase
(2011) Cell, 144 (5), pp. 703-718. Cited 4 times.

Mader, C.C., Oser, M., Magalhaes, M.A.O., Bravo-Cordero, J.J., Condeelis, J., Koleske, A.J., Gil-Henn, H.
An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion
(2011) Cancer Research, 71 (5), pp. 1730-1741.

Osborne, C.K., Neven, P., Dirix, L.Y., Mackey, J.R., Robert, J., Underhill, C., Schiff, R., Gutierrez, C., Migliaccio, I., Anagnostou, V.K., Rimm, D.L., Magill, P., Sellers, M.
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: A randomized phase II study
(2011) Clinical Cancer Research, 17 (5), pp. 1147-1159.